cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Phathom Pharmaceuticals Inc
1 own
4 watching
Current Price
$6.99
$-0.11
(-1.55%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
535.93M
52-Week High
52-Week High
17.01900
52-Week Low
52-Week Low
5.84000
Average Volume
Average Volume
0.41M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization535.93M
icon52-Week High17.01900
icon52-Week Low5.84000
iconAverage Volume0.41M
iconDividend Yield--
iconP/E Ratio--
What does the Phathom Pharmaceuticals Inc do?
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Read More
How much money does Phathom Pharmaceuticals Inc make?
News & Events about Phathom Pharmaceuticals Inc.
Globe Newswire
5 months ago
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. (NASDAQ: IART), Chinook Therapeutics, Inc. (NASDAQ: KDNY), Phathom Pharmaceuticals, Inc. (NASDAQ...
Globe Newswire
5 months ago
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023Combined launch of vonoprazan for Erosive GERD and H. pylori indications planned for Q4 2023, if approved FLORHAM PARK, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical ...
PR Newswire
5 months ago
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws PR...
Ticker Report
7 months ago
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT Get Rating) COO Azmi Nabulsi acquired 10,000 shares of the businesss stock in a transaction that occurred on Tuesday, April 11th. The stock was bought at an average cost of $8.26 per share, for a total transaction of $82,600.00. Following the...
Zolmax
7 months ago
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT Get Rating) COO Azmi Nabulsi acquired 10,000 shares of the businesss stock in a transaction that occurred on Tuesday, April 11th. The stock was bought at an average cost of $8.26 per share, for a total transaction of $82,600.00. Following the completion of ...
Frequently Asked Questions
Frequently Asked Questions
What is Phathom Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Phathom Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Phathom Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Phathom Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Phathom Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Phathom Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Phathom Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Phathom Pharmaceuticals Inc?
plus_minus_icon
What percentage is Phathom Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Phathom Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$6.99
$-0.11
(-1.55%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$12.59
$0.50 (4.14 %)
OLEMA PHARMACEUTICALS INC
OLEMA PHARMACEUTICALS INC
$13.95
$0.77 (5.84 %)
Calliditas Therapeutics AB
Calliditas Therapeutics AB
$17.35
$-0.85 (-4.67 %)
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
$12.72
$0.40 (3.25 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$12.59
$0.50 (4.14 %)
OLEMA PHARMACEUTICALS INC
OLEMA PHARMACEUTICALS INC
$13.95
$0.77 (5.84 %)
Calliditas Therapeutics AB
Calliditas Therapeutics AB
$17.35
$-0.85 (-4.67 %)
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
$12.72
$0.40 (3.25 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00